Robust SARS-CoV-2-specific and heterologous immune responses in vaccine-naïve residents of long-term care facilities who survive natural infection.
Journal
Nature aging
ISSN: 2662-8465
Titre abrégé: Nat Aging
Pays: United States
ID NLM: 101773306
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
19
08
2021
accepted:
14
04
2022
medline:
1
5
2023
pubmed:
29
4
2023
entrez:
28
4
2023
Statut:
ppublish
Résumé
We studied humoral and cellular immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 152 long-term care facility staff and 124 residents over a prospective 4-month period shortly after the first wave of infection in England. We show that residents of long-term care facilities developed high and stable levels of antibodies against spike protein and receptor-binding domain. Nucleocapsid-specific responses were also elevated but waned over time. Antibodies showed stable and equivalent levels of functional inhibition against spike-angiotensin-converting enzyme 2 binding in all age groups with comparable activity against viral variants of concern. SARS-CoV-2 seropositive donors showed high levels of antibodies to other beta-coronaviruses but serostatus did not impact humoral immunity to influenza or other respiratory syncytial viruses. SARS-CoV-2-specific cellular responses were similar across all ages but virus-specific populations showed elevated levels of activation in older donors. Thus, survivors of SARS-CoV-2 infection show a robust and stable immunity against the virus that does not negatively impact responses to other seasonal viruses.
Identifiants
pubmed: 37118449
doi: 10.1038/s43587-022-00224-w
pii: 10.1038/s43587-022-00224-w
pmc: PMC10154219
doi:
Substances chimiques
Influenza Vaccines
0
Antibodies
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
536-547Subventions
Organisme : Wellcome Trust
ID : 222907/Z/21/Z
Pays : United Kingdom
Informations de copyright
© 2022. The Author(s).
Références
SN Compr Clin Med. 2020;2(12):2658-2669
pubmed: 33169110
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
Lancet Infect Dis. 2021 Nov;21(11):1529-1538
pubmed: 34174193
Sci Immunol. 2019 Nov 1;4(41):
pubmed: 31672862
Cell Rep. 2020 Jun 2;31(9):107725
pubmed: 32426212
Nat Immunol. 2021 May;22(5):620-626
pubmed: 33674800
J Infect. 2020 Sep;81(3):411-419
pubmed: 32504743
Nat Immunol. 2022 Jan;23(1):40-49
pubmed: 34937928
Sci Immunol. 2020 Oct 8;5(52):
pubmed: 33033172
Immun Ageing. 2021 Feb 17;18(1):7
pubmed: 33596958
PLoS Med. 2021 Jul 6;18(7):e1003656
pubmed: 34228725
Science. 2020 Dec 11;370(6522):1339-1343
pubmed: 33159009
Nat Rev Cardiol. 2018 Sep;15(9):505-522
pubmed: 30065258
Cell. 2021 Apr 29;184(9):2384-2393.e12
pubmed: 33794143
Nat Rev Immunol. 2006 Oct;6(10):741-50
pubmed: 16977339
Age Ageing. 2021 Jun 28;50(4):1019-1028
pubmed: 33710281
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32381641
Lancet Healthy Longev. 2021 Sep;2(9):e544-e553
pubmed: 34430954
Cell Rep Med. 2021 Jul 20;2(7):100354
pubmed: 34250512
Lancet Infect Dis. 2020 Dec;20(12):1390-1400
pubmed: 32979318
Wellcome Open Res. 2020 Oct 7;5:232
pubmed: 33564722
Euro Surveill. 2021 Feb;26(5):
pubmed: 33541486
Science. 2019 Nov 1;366(6465):599-606
pubmed: 31672891
Age Ageing. 2021 Jan 8;50(1):25-31
pubmed: 32951042
Sci Rep. 2021 Feb 23;11(1):4358
pubmed: 33623057
Lancet Healthy Longev. 2021 Jun;2(6):e362-e370
pubmed: 34104901
J Gerontol A Biol Sci Med Sci. 2020 Oct 15;75(11):2224-2230
pubmed: 32687551
BMC Med. 2021 Mar 5;19(1):71
pubmed: 33663498
Nat Commun. 2020 Sep 17;11(1):4704
pubmed: 32943637